(Q35752864)

10 August 2017

1 reference

title

Glycopeptide antibiotics: from conventional molecules to new derivatives (English)

1 reference

10 August 2017

0 references

Françoise Van Bambeke

1

1 reference

10 August 2017

Yves Van Laethem

2

1 reference

10 August 2017

Patrice Courvalin

3

1 reference

10 August 2017

Paul M Tulkens

4

1 reference

10 August 2017

language of work or name

1 reference

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

64

1 reference

10 August 2017

issue

9

1 reference

10 August 2017

page(s)

913-936

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200464090-00001

10 August 2017

exact match

0 references

cites work

Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aure

1 reference

12 December 2020

High prevalence of colonization with vancomycin- and pristinamycin-resistant enterococci in healthy humans and pigs in The Netherlands: is the addition of antibiotics to animal feeds to blame?

1 reference

12 December 2020

Antibiotic resistance in staphylococci.

1 reference

12 December 2020

Amides of de-acetylglucosaminyl-deoxy teicoplanin active against highly glycopeptide-resistant enterococci. Synthesis and antibacterial activity

1 reference

12 December 2020

In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide

1 reference

12 December 2020

Phosphinate analogs of D-, D-dipeptides: slow-binding inhibition and proteolysis protection of VanX, a D-, D-dipeptidase required for vancomycin resistance in Enterococcus faecium

1 reference

12 December 2020

Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis

1 reference

12 December 2020

In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci

1 reference

12 December 2020

Pharmacokinetics of teicoplanin in patients undergoing continuous ambulatory peritoneal dialysis.

1 reference

12 December 2020

Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.

1 reference

12 December 2020

Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance

1 reference

12 December 2020

Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci

1 reference

12 December 2020

The post-antibiotic effect of teicoplanin: monotherapy and combination studies

1 reference

12 December 2020

Vancomycin: an update

1 reference

12 December 2020

Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.

1 reference

12 December 2020

Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium

1 reference

12 December 2020

In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates

1 reference

12 December 2020

Clinical pharmacokinetics of teicoplanin

1 reference

12 December 2020

New trends in Staphylococcus aureus infections: glycopeptide resistance in hospital and methicillin resistance in the community

1 reference

12 December 2020

Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities

1 reference

12 December 2020

Epidemiology of resistance to antibiotics. Links between animals and humans

1 reference

12 December 2020

Mutations leading to increased levels of resistance to glycopeptide antibiotics in VanB-type enterococci.

1 reference

12 December 2020

The role of glycopeptide antibiotics in the treatment of infective endocarditis

1 reference

12 December 2020

Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice

1 reference

12 December 2020

Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion

1 reference

12 December 2020

In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.

1 reference

12 December 2020

Prevalence of vancomycin-resistant enterococci in Europe.

1 reference

12 December 2020

Dalbavancin (Biosearch Italia/Versicor).

1 reference

12 December 2020

Hybrid glycopeptide antibiotics

1 reference

12 December 2020

Vancomycin-resistant enterococci

1 reference

12 December 2020

Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.

1 reference

12 December 2020

Molecular basis of the activity of antibiotics of the vancomycin group

1 reference

12 December 2020

Structure-activity relationships of vancomycin-type glycopeptide antibiotics

1 reference

12 December 2020

1 reference

12 December 2020

The structure of an asymmetric dimer relevant to the mode of action of the glycopeptide antibiotics

1 reference

12 December 2020

Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics

1 reference

12 December 2020

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

1 reference

12 December 2020

Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection

1 reference

12 December 2020

VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405

1 reference

12 December 2020

Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin

1 reference

12 December 2020

Nosocomial enterococci resistant to vancomycin--United States, 1989-1993.

1 reference

12 December 2020

A prospective study of adverse reactions associated with vancomycin therapy

1 reference

12 December 2020

Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis

1 reference

12 December 2020

In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic

1 reference

12 December 2020

Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model

1 reference

12 December 2020

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

1 reference

12 December 2020

Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147.

1 reference

12 December 2020

Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.

1 reference

12 December 2020

Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides

1 reference

12 December 2020

An LY333328-dependent strain of Enterococcus faecalis isolated from a blood culture

1 reference

12 December 2020

In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria

1 reference

12 December 2020

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

1 reference

12 December 2020

A vancomycin monitoring program at a community hospital.

1 reference

12 December 2020

Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene

1 reference

12 December 2020

Glycopeptide-resistant Staphylococcus aureus

1 reference

12 December 2020

Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages

1 reference

12 December 2020

In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci.

1 reference

12 December 2020

In vitro activity of LY 333328 against anaerobic gram-positive bacteria

1 reference

12 December 2020

VanD-type glycopeptide-resistant Enterococcus faecium BM4339.

1 reference

12 December 2020

In vitro activity of the semisynthetic glycopeptide amide MDL 63,246

1 reference

12 December 2020

Vancomycin-dependent Enterococcus faecalis clinical isolates and revertant mutants

1 reference

12 December 2020

Reducing vancomycin use utilizing a computer guideline: results of a randomized controlled trial

1 reference

12 December 2020

In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin

1 reference

12 December 2020

Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients

1 reference

12 December 2020

Safety and tolerability of quinupristin/dalfopristin: administration guidelines

1 reference

12 December 2020

Vancomycin-resistant enterococci: why are they here, and where do they come from?

1 reference

12 December 2020

The structural biology of molecular recognition by vancomycin

1 reference

12 December 2020

Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis

1 reference

12 December 2020

Pneumococcal susceptibility to meropenem in a mid-south children's hospital.

1 reference

12 December 2020

In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study

1 reference

12 December 2020

Hematologic effects of linezolid: summary of clinical experience

1 reference

12 December 2020

Antibacterial activities and modes of action of vancomycin and related glycopeptides

1 reference

12 December 2020

Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis

1 reference

12 December 2020

Glycopeptide prescribing in a tertiary referral paediatric hospital and applicability of hospital infection control practices advisory committee (HICPAC) guidelines to children.

1 reference

12 December 2020

Uncommon vancomycin-induced side effects

1 reference

12 December 2020

Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.

1 reference

12 December 2020

Rates of carriage of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in an outpatient population

1 reference

12 December 2020

Molecular characterization of vancomycin-resistant enterococci from hospitalized patients and poultry products in The Netherlands.

1 reference

12 December 2020

Structure, biochemistry and mechanism of action of glycopeptide antibiotics

1 reference

12 December 2020

The role of sugar residues in molecular recognition by vancomycin

1 reference

12 December 2020

Crystal structure of vancomycin

1 reference

12 December 2020

Selection of glycopeptide-resistant mutants of VanB-type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis

1 reference

12 December 2020

Does the dose matter?

1 reference

12 December 2020

Curtailing unnecessary vancomycin usage in a hospital with high rates of methicillin resistant Staphylococcus aureus infections

1 reference

12 December 2020

Glycopeptide resistance in enterococci

1 reference

12 December 2020

Glycopeptide-resistant staphylococci.

1 reference

12 December 2020

Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium

1 reference

12 December 2020

Decreased incidence of VanA-type vancomycin-resistant enterococci isolated from poultry meat and from fecal samples of humans in the community after discontinuation of avoparcin usage in animal husbandry.

1 reference

12 December 2020

New Semisynthetic Glycopeptides MDL 63,246 and MDL 63,042, and Other Amide Derivatives of Antibiotic A-40,926 Active against Highly Glycopeptide-resistant VanA Enterococci

1 reference

12 December 2020

Synthesis and biological evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria: target-accelerated combinatorial synthesis.

1 reference

12 December 2020

Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981

1 reference

12 December 2020

Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis

1 reference

12 December 2020

In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci

1 reference

12 December 2020

Cooperative binding interactions of glycopeptide antibiotics

1 reference

12 December 2020

Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark

1 reference

12 December 2020

Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection

1 reference

12 December 2020

Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus

1 reference

12 December 2020

Treatment options for vancomycin-resistant enterococcal infections

1 reference

12 December 2020

A rational strategy for enhancing the affinity of vancomycin towards depsipeptide ligands

1 reference

12 December 2020

Arthralgias and myalgias related to quinupristin-dalfopristin administration

1 reference

12 December 2020

Vancomycin, teicoplanin, and ramoplanin: synthetic and mechanistic studies

1 reference

12 December 2020

Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model

1 reference

12 December 2020

Chromatographically purified vancomycin: therapy of serious infections caused by Staphylococcus aureus and other gram-positive bacteria.

1 reference

12 December 2020

Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis.

1 reference

12 December 2020

Historical yearly usage of vancomycin.

1 reference

12 December 2020

Recommendations for preventing the spread of vancomycin resistance

1 reference

12 December 2020

The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units

1 reference

12 December 2020

Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients.

1 reference

12 December 2020

Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity

1 reference

12 December 2020

Mechanism of uptake of deglucoteicoplanin amide derivatives across outer membranes of Escherichia coli and Pseudomonas aeruginosa

1 reference

12 December 2020

Structural modifications of glycopeptide antibiotics

1 reference

12 December 2020

An analysis of the origins of a cooperative binding energy of dimerization

1 reference

12 December 2020

National guidelines for the judicious use of glycopeptides in Belgium.

1 reference

12 December 2020

Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study

1 reference

12 December 2020

Failure of cefotaxime and meropenem to eradicate meningitis caused by an intermediately susceptible Streptococcus pneumoniae strain

1 reference

12 December 2020

Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci.

1 reference

12 December 2020

Staphylococcus aureus resistant to vancomycin--United States, 2002.

1 reference

12 December 2020

The structural basis for induction of VanB resistance

1 reference

12 December 2020

Selective cleavage of D-Ala-D-Lac by small molecules: re-sensitizing resistant bacteria to vancomycin

1 reference

12 December 2020

Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics

1 reference

12 December 2020

Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala.

1 reference

12 December 2020

Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in an in vitro infection model

1 reference

12 December 2020

Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania

1 reference

12 December 2020

Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium

1 reference

12 December 2020

Quinupristin-dalfopristin and linezolid: evidence and opinion

1 reference

12 December 2020

Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model

1 reference

12 December 2020

Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis

1 reference

12 December 2020

Genetic characterization of vanG, a novel vancomycin resistance locus of Enterococcus faecalis

1 reference

12 December 2020

Excessive use of vancomycin: a successful intervention strategy at an academic medical center

1 reference

12 December 2020

The comparative efficacy and safety of teicoplanin and vancomycin

1 reference

12 December 2020

Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus

1 reference

12 December 2020

Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic

1 reference

12 December 2020

Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin

1 reference

12 December 2020

Conjugal transfer of the vancomycin resistance determinant vanB between enterococci involves the movement of large genetic elements from chromosome to chromosome

1 reference

12 December 2020

Phosphonamidate and phosphothioate dipeptides as potential inhibitors of VanX.

1 reference

12 December 2020

Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin

1 reference

12 December 2020

Novel glycopeptide antibiotics: N-alkylated derivatives active against vancomycin-resistant enterococci.

1 reference

12 December 2020

Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA.

1 reference

12 December 2020

Have the oxazolidinones lived up to their billing? Future perspectives for this antibacterial class.

1 reference

12 December 2020

In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis

1 reference

12 December 2020

Mechanism of action of oritavancin and related glycopeptide antibiotics

1 reference

12 December 2020

Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections

1 reference

12 December 2020

Acquired and intrinsic glycopeptide resistance in enterococci

1 reference

12 December 2020

Vancomycin-resistant Staphylococcus aureus: a real and present danger?

1 reference

12 December 2020

In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent

1 reference

12 December 2020

Effect of LY333328 against vancomycin-resistant Enterococcus faecium in a rat central venous catheter-associated infection model

1 reference

12 December 2020

Glycopeptide derivatives

1 reference

12 December 2020

Glycopeptide tolerance in Staphylococcus aureus.

1 reference

12 December 2020

Oritavancin. Eli Lilly & Co.

1 reference

12 December 2020

Synthesis and mode of action of hydrophobic derivatives of the glycopeptide antibiotic eremomycin and des-(N-methyl-D-leucyl)eremomycin against glycopeptide-sensitive and -resistant bacteria

1 reference

12 December 2020

10.2165/00003495-200464090-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1002828094

0 references

1 reference